BIOMAT Database Logo BIOMAT Database Logo

Neoadjuvant Anti-PD-1 Immunotherapy Leads to Survival Benefit in Recurrent Glioblastoma. 2019

W Christopher Newman, and Nduka M Amankulor
Department of Neurological Surgery University of Pittsburgh Medical Center Pittsburgh, Pennsylvania.

UI MeSH Term Description Entries

Related Publications

W Christopher Newman, and Nduka M Amankulor
Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma.
December 2019, Translational cancer research,
W Christopher Newman, and Nduka M Amankulor
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
March 2019, Nature medicine,
W Christopher Newman, and Nduka M Amankulor
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
December 2021, Nature cancer,
W Christopher Newman, and Nduka M Amankulor
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
March 2022, Nature cancer,
W Christopher Newman, and Nduka M Amankulor
Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
June 2019, Journal of neuro-oncology,
W Christopher Newman, and Nduka M Amankulor
Immunotherapy: Benefit with anti-PD-L1.
February 2017, Nature reviews. Clinical oncology,
W Christopher Newman, and Nduka M Amankulor
Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors.
March 2021, MedComm,
W Christopher Newman, and Nduka M Amankulor
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
March 2019, Nature medicine,
W Christopher Newman, and Nduka M Amankulor
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.
February 2020, eLife,
W Christopher Newman, and Nduka M Amankulor
Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.
April 2018, Oncotarget,
Copied contents to your clipboard!